Sayegh M H, Carpenter C B
Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Int Rev Immunol. 1996;13(3):221-9. doi: 10.3109/08830189609061749.
It is now clear from animal studies that indirect allorecognition occurs during allograft rejection and that this pathway plays a role in mediating the rejection process. Whether this pathway is the dominant pathway responsible for chronic rejection remains to be established, but this is an intriguing hypothesis that may have major implications for development of novel therapies for this disorder. In addition, there are data to indicate that indirect allorecognition may play a role in maintenance of allograft acceptance, and that provision of appropriate MHC peptides via different routes can result in potent degrees of specific allo-tolerance. Expanded experimentation in animals and in humans is therefore in order; first, to dissect more closely the molecular basis of allorecognition and establish the role of the indirect pathway in acute versus chronic rejection, and second to utilize the immunomodulatory properties of MHC peptides or other novel strategies which targets indirect allorecognition in promoting graft acceptance.
目前,动物研究已明确,间接同种异体识别在同种异体移植排斥反应中会发生,且该途径在介导排斥过程中发挥作用。这条途径是否是导致慢性排斥反应的主要途径仍有待确定,但这是一个有趣的假说,可能对开发针对该疾病的新疗法具有重要意义。此外,有数据表明间接同种异体识别可能在维持同种异体移植接受方面发挥作用,并且通过不同途径提供适当的主要组织相容性复合体(MHC)肽可导致强效的特异性同种异体耐受。因此,需要在动物和人类中进行更多实验;首先,更深入地剖析同种异体识别的分子基础,并确定间接途径在急性排斥与慢性排斥中的作用;其次,利用MHC肽的免疫调节特性或其他针对间接同种异体识别的新策略来促进移植接受。